Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

	PATIENT INFORMATION	PHYSICIAN INFORMATION	
Name		Name	
ID Number	г	Specialty	
D.O.B.	/MM/DD/YYYY □Male □Female	Address	
Diagnosis		City/State/Zip	
Drug Name Cinqair		Phone: Fax:	
Dose and Quantity		NPI	
Directions		Contact Person	
Date of Service(s)		Contact Person Phone / Ext.	
STEP 1: I	DISEASE STATE INFORMATION	THORE / EACH	
Par	rvice area. If you are not a provider in the geographic so FEP member's benefit requirements. this member's FEP coverage primary or secondary coverage if primary, continue with question set.	through this process. will be serviced by a provider within the health plan's geographic ervice area, please contact the health plan for questions regarding	
	e of Care: At what location will the member be receiving the request Physician's office, home infusion, non-hospital affilia Outpatient hospital infusion center. Please provide the receive this medication in a hospital outpatient setting. Other. Please specify.		
	iteria Questions: What is the patient's diagnosis? ☐ Asthma with an eosinophilic phenotype ☐ Other diagnosis (please specify):		
2.	Is Cinquir being used to treat other eosinophilic conditions? Yes No		
3.	Is Cinquir being used for the relief of acute bronchospasm or status asthmaticus? Yes No		
4.	Is Cinquir being used in combination with another monoclonal antibody for the treatment of asthma? Yes* No *If YES, specify the medication:		

	NO – this is INITIATION of therapy, please answer the follows:	wing questions:		
	a. Is the patient's diagnosis severe? ☐ Yes ☐ No			
	b. Has the patient had inadequate control of asthma symptom			
	the past six months? \square Yes \square No*	id inhaler in combination with a long acting beta2-agonist within		
		ymptoms after a minimum of three months of compliant use		
	defined as greater than or equal to 50% adherence with a co			
	muscarinic antagonist within the past six months? Yes			
	c. Does the patient have an eosinophil count greater than or e			
	*If NO, does the patient have an eosinophil count greater than or equal to 300 cells/mcL in the past 12 months?			
	d. Yes No Is Cinqair being administered by a healthca anaphylaxis and will the patient be monitored for an appro			
	YES – this is a PA renewal for CONTINUATION of therapy			
	a. Has the patient had a documented decrease in exacerbation			
	 b. Has the patient decreased utilization of rescue medications c. Has the patient been compliant on Cinquir therapy? ☐ Yes 			
	c. Thas the patient occir compilant on emqan therapy:	S = 1\0		
CI.				
Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required) Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.				
Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function				
Physician's Nan	ne Physician Signature	Date		
Step 2:	☐ Form Completely Filled Out	☐ Attach test results		
Checklist	☐ Provide chart notes	Attach test fesuits		
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320		

5. Has the patient been on Cinquir continuously for the last 4 months, excluding samples? Please select answer below: